Abstract 16402: Feasibility and Safety of Uninterrupted Rivaroxaban in Patients Undergoing Radiofrequency Ablation for Long Standing Persistent Atrial Fibrillation
Introduction: Periprocedural anticoagulation management is key to minimize bleeding and thromboembolic complications during and after radiofrequency catheter ablation. Uninterrupted strategies with warfarin in high risk patients have shown superiority over interrupted strategies.
We sought to assess the safety and feasibility uninterrupted rivaroxaban during atrial fibrillation (AF) ablation in patients with long standing persistent atrial fibrillation.
Methods: One hundred and ninety six (196) consecutive patients undergoing AF ablation with uninterrupted rivaroxaban (last dose taken with food the night before the procedure and the following dose taken the night of the procedure) were matched by age and sex with an equal number of patients undergoing AF ablation with uninterrupted warfarin on a “therapeutic range”. All patients underwent pulmonary vein antrum isolation and ablation of non pulmonary vein triggers as disclosed by isoproterenol challenge test.
Results: Baseline characteristics and procedural variables were similar between groups. Mean INR in warfarin group was 2.2 ± 0.5. CHADS2 Score was ≥ 2 in 141 (72%) in the rivaroxaban group and 130 (66%) in the warfarin patients (p=0.20). One pericardial tamponade and one groin hematoma occurred in rivaroxaban group while 2 patients in warfarin group developed groin hematoma. One TIA with positive MRI was present in the rivaroxaban group.
Conclusions: Uninterrupted rivaroxaban therapy appears to be as safe and efficacious as uninterrupted warfarin strategy in preventing bleeding and thromboembolic events in patients undergoing long standing persistent AF ablation.
Author Disclosures: L. Di Biase: Honoraria; Modest; Biotronik, AtriCure Inc., EpiEP.. Consultant/Advisory Board; Modest; St. Jude Medical, Biosense Webster, Inc., Hansen Medical. C. Trivedi: None. P. Mohanty: None. S. Mohanty: None. R. Bai: None. P. Santangeli: None. J. Sanchez: None. R. Horton: None. G. Gallinghouse: None. J. Zagrodzky: None. S. Hao: None. R. Hongo: None. S. Beheiry: None. D. Lakkireddy: None. M. Reddy: None. J. Viles-Gonzalez: None. J. Burkhardt: None. A. Natale: Speakers Bureau; Modest; Medtronic, Inc., Biotronik, Boston Scientific Corp.. Honoraria; Modest; Janssen Pharmaceuticals, Biosense Webster, Inc., St. Jude Medical..
- © 2014 by American Heart Association, Inc.